Merck (MRK) Income from Non-Controlling Interests (2009 - 2026)
Merck (MRK) reported Income from Non-Controlling Interests of -$3.0 million for Q1 2026, down 150.0% year-over-year from $6.0 million in Q1 2025, and down 200.0% quarter-over-quarter from -$1.0 million in Q4 2025.
Merck (MRK) Income from Non-Controlling Interests (2009 - 2026) Analysis & Trends
Merck (MRK) has 18 years of Income from Non-Controlling Interests data on file, last reported at -$3.0 million in Q1 2026.
- Income from Non-Controlling Interests for Q1 2026 came in at -$3.0 million, down 150.0% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.0 million (down 105.88% YoY), and the FY2025 annual result was $9.0 million, down 43.75% from the prior year.
- Income from Non-Controlling Interests slipped to -$3.0 million in Q1 2026 per MRK's latest filing, from -$1.0 million in the prior quarter.
- Over five years, Income from Non-Controlling Interests peaked at $6.0 million in Q2 2024 and troughed at -$3.0 million in Q1 2022.
- A 5-year average of $2.6 million and a median of $3.5 million in 2023 frame the typical range for Income from Non-Controlling Interests.
- The sharpest annual moves came in 2022 and 2025: Income from Non-Controlling Interests surged 400.0% in 2022, then plunged 200.0% in 2025.
- A 5-year view of Income from Non-Controlling Interests shows it stood at $1.0 million in 2022, then surged by 400.0% to $5.0 million in 2023, then slumped by 80.0% to $1.0 million in 2024, then sank by 200.0% to -$1.0 million in 2025, then sank by 200.0% to -$3.0 million in 2026.
- Business Quant data shows MRK's Income from Non-Controlling Interests at -$3.0 million in Q1 2026, -$1.0 million in Q4 2025, and $2.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 2.48 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | - |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 2.00 Mn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | -3.00 Mn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | - |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 8.00 Mn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 1.00 Mn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | 415.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.00 Mn |
| Dec 31, 2025 | -1.00 Mn |
| Sep 30, 2025 | 2.00 Mn |
| Jun 30, 2025 | 1.00 Mn |
| Mar 31, 2025 | 6.00 Mn |
| Dec 31, 2024 | 1.00 Mn |
| Sep 30, 2024 | 4.00 Mn |
| Jun 30, 2024 | 6.00 Mn |
| Mar 31, 2024 | 5.00 Mn |
| Sep 30, 2023 | 5.00 Mn |
| Jun 30, 2023 | 3.00 Mn |
| Mar 31, 2023 | 4.00 Mn |
| Dec 31, 2022 | 1.00 Mn |
| Sep 30, 2022 | 5.00 Mn |
| Jun 30, 2022 | 5.00 Mn |
| Mar 31, 2022 | -3.00 Mn |
| Dec 31, 2021 | 4.00 Mn |
| Sep 30, 2021 | 4.00 Mn |
| Jun 30, 2021 | 1.00 Mn |
| Mar 31, 2021 | 4.00 Mn |